Novel 21-aminosteroids prevent tumour associated neurological dysfunction.
The efficacy of the potent lipid peroxidation inhibitors U-74006F and U-78517F in the treatment of blood-tumour barrier permeability and tumour associated neurological dysfunction was evaluated. Rats with stereotactically implanted Walker 256 tumours were treated with methylprednisolone (MP), U-74006F, U-78517F, or vehicle. (0.05 N HCl) on days 6 through 10 following implantation. Neurologic function and vascular permeability was assessed on day 10. U-74006F and MP were equally effective at preventing neurologic dysfunction compared to control (p less than 0.01). U-78517F was slightly less effective than U-74006F and MP but was significantly better than vehicle in preventing neurological dysfunction. MP resulted in a significant decrease in tumour vascular permeability (p less than 0.006) while the lipid peroxidation inhibitors had no effect on permeability.
King
W A
WA
Brain Research Institute, Jonsson Cancer Center, Los Angeles, California.
Black
K L
KL
Ikezaki
K
K
Conklin
S
S
Becker
D P
DP
D000818:Animals; D001932:Brain Neoplasms / Q000098:blood supply / Q000503:physiopathology*; D002199:Capillary Permeability; D002839:Chromans / Q000494:pharmacology*; D005260:Female; D008054:Lipid Peroxides / Q000037:antagonists & inhibitors; D008775:Methylprednisolone / Q000494:pharmacology*; D009420:Nervous System / Q000503:physiopathology*; D010879:Piperazines / Q000494:pharmacology*; D011281:Pregnatrienes / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values
D002839:Chromans; D008054:Lipid Peroxides; D010879:Piperazines; D011281:Pregnatrienes; C066382:U 78517F; D008775:Methylprednisolone; C053355:tirilazad